Combination treatment for cancer
AssigneesGlaxoSmithKline Intellectual Property Development Limited, Board of Regents, The University of Texas System
InventorsMaria Angelica CORTEZ, Sharareh NIKNAM, Jonathan E. SCHOENHALS, James W. WELSH, Niranjan YANAMANDRA
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method of treatment involving the combination of an anti-OX40 antigen binding protein (e.g., an anti-OX40 agonist antibody) and/or radiotherapy, for use in treating a cancer. The cancer may include anti-PD-1 resistance.
Claims23
-95. (canceled)
A method of treating human cancer, the method comprising:
- (i) administering an anti-human OX40 antigen binding protein comprising:
- (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1;
- (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2;
- (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3;
- (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7;
- (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8;
- and (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9;
- and,
- (ii) administering radiotherapy;
- wherein a therapeutically effective amount of the anti-human OX40 antigen binding protein and the radiotherapy is administered.
A method of treating a human solid tumor, the method comprising:
- (i) administering an anti-human OX40 monoclonal antibody, the antibody comprising:
- (a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1;
- (b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2;
- (c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3;
- (d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7;
- (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8;
- and, (f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9;
- (ii) administering radiotherapy;
- and,
- (iii) administering an anti-PD-1 monoclonal antibody;
- wherein a therapeutically effective amount of the anti-human OX40 monoclonal antibody, the radiotherapy, and the anti-PD-1 monoclonal antibody is administered.
A method for reducing tumor size in a human in need thereof, the method comprising:
- (i) administering an anti-human OX40 monoclonal antibody;
- (ii) administering radiotherapy;
- and, (iii) administering an anti-PD-1 monoclonal antibody.
Dependencies are inferred from the claim text.